Target_Summary_ID stringclasses 200
values | Target_Sentence_Index stringlengths 4 7 | External stringclasses 2
values | Target_Sentence_factual stringlengths 19 592 | Target_Sentence_non_factual stringlengths 19 592 | Original_Abstract stringclasses 200
values |
|---|---|---|---|---|---|
t196 | t196_8 | yes | We did not find an explanation for this when looking into other outcomes reported in the primary studies. | We did not find an explanation for this when ignoring other outcomes reported in the primary studies. | Several beta‐lactams are recommended as single agents for the treatment of febrile neutropenia. Objectives To compare the effectiveness of different anti‐pseudomonal beta‐lactams as single agents in the treatment of febrile neutropenia. To compare the development of bacterial resistance, bacterial and fungal superinfec... |
t196 | t196_9 | no | Piperacillin‐tazobactam resulted in lower mortality than other antibiotics. | Piperacillin‐tazobactam resulted in higher mortality than other antibiotics. | Several beta‐lactams are recommended as single agents for the treatment of febrile neutropenia. Objectives To compare the effectiveness of different anti‐pseudomonal beta‐lactams as single agents in the treatment of febrile neutropenia. To compare the development of bacterial resistance, bacterial and fungal superinfec... |
t196 | t196_10 | no | The other antibiotics (ceftazidime, imipenem and meropenem) showed comparable efficacy, with a lower rate of antibiotic changes for imipenem or meropenem and a higher rate of severe diarrhea with these two antibiotics. | The other antibiotics (ceftazidime, imipenem and meropenem) showed comparable efficacy, with a higher rate of antibiotic changes for imipenem or meropenem and a higher rate of severe diarrhea with these two antibiotics. | Several beta‐lactams are recommended as single agents for the treatment of febrile neutropenia. Objectives To compare the effectiveness of different anti‐pseudomonal beta‐lactams as single agents in the treatment of febrile neutropenia. To compare the development of bacterial resistance, bacterial and fungal superinfec... |
t196 | t196_11 | yes | We conclude that piperacillin‐tazobactam might be the preferred antibiotic for the treatment of cancer patients with fever and neutropenia and that cefepime should not be used. | We conclude that piperacillin‐tazobactam might be the preferred antibiotic for the treatment of cancer patients with fever and neutropenia and that amoxicillin should not be used. | Several beta‐lactams are recommended as single agents for the treatment of febrile neutropenia. Objectives To compare the effectiveness of different anti‐pseudomonal beta‐lactams as single agents in the treatment of febrile neutropenia. To compare the development of bacterial resistance, bacterial and fungal superinfec... |
t196 | t196_12 | yes | Antibiotic selection (other than cefepime) depends on the individual patient and the type of bacteria prevalent in the specific hospital. | Antibiotic selection (other than amoxicillin) depends on the individual patient and the type of bacteria prevalent in the specific hospital. | Several beta‐lactams are recommended as single agents for the treatment of febrile neutropenia. Objectives To compare the effectiveness of different anti‐pseudomonal beta‐lactams as single agents in the treatment of febrile neutropenia. To compare the development of bacterial resistance, bacterial and fungal superinfec... |
t197 | t197_1 | yes | Multiple myeloma (also known as myeloma or plasma cell myeloma) is a B‐cell malignancy or, more precisely, plasma cell neoplasm. | Multiple myeloma (also known as myeloma or plasma cell myeloma) is a T‐cell malignancy or, more precisely, plasma cell neoplasm. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_2 | yes | This cancer grows inside or outside of bones. | This cancer does not grow inside or outside of bones. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_3 | yes | The bone damage, or osteolytic lesions, may lead to fractures of the long bones or compression fractures in the spine. | The bone damage, or osteolytic lesions, may not lead to fractures of the long bones or compression fractures in the spine. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_4 | yes | The mechanism of bone destruction appears to be related to increased bone resorption by cells called osteoclasts. | The mechanism of bone destruction appears to be related to decreased bone resorption by cells called osteoclasts. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_5 | no | Bisphosphonates are drugs that can inhibit bone resorption by reducing the number and activity of osteoclasts. | Bisphosphonates are drugs that can promote bone resorption by reducing the number and activity of osteoclasts. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_6 | yes | Use of bisphosphonates in participants with multiple myeloma did not improve overall survival or disease progression‐free survival. | Use of bisphosphonates in participants with multiple myeloma did not worsen overall survival or disease progression‐free survival. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_7 | yes | Use of bisphosphonates in participants with multiple myeloma reduces overall fractures, fractures of the vertebra but not the non‐vertebral fractures. | Use of bisphosphonates in participants with multiple myeloma increases overall fractures, fractures of the vertebra but not the non‐vertebral fractures. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_8 | yes | Bisphosphonates also alleviates pain without many side effects except a significant increase in reduced blood flow to bones of the jaw resulting in decay of the bone also called osteonecrosis. | Bisphosphonates also alleviates pain without many side effects except a significant decrease in reduced blood flow to bones of the jaw resulting in decay of the bone also called osteonecrosis. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_9 | yes | Overall, for every 1000 participants treated with bisphosphonates, about one patient will suffer from the osteonecrosis of the jaw. | Overall, for every 1200 participants treated with bisphosphonates, about one patient will suffer from the osteonecrosis of the jaw. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_10 | yes | Zoledronate was found to be better than etidronate and placebo, but not superior to pamidronate or clodronate for improving overall survival and other outcomes such as fractures in general or specifically fractures of vertebra. | Zoledronate was found to be better than etidronate and placebo, but not superior to alendronate or clodronate for improving overall survival and other outcomes such as fractures in general or specifically fractures of vertebra. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t197 | t197_11 | no | There was no evidence of superiority of any specific aminobisphosphonate (zoledronate, pamidronate or ibandronate) or non‐aminobisphosphonate (etidronate or clodronate) for any outcome. | There was no evidence of superiority of any specific aminobisphosphonate (alendronate, pamidronate or ibandronate) or non‐aminobisphosphonate (etidronate or clodronate) for any outcome. | Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane ... |
t198 | t198_1 | yes | Ventilators are machines that breathe for patients. | Ventilators are machines that suffocate patients. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_2 | yes | The ventilator tube goes into the mouth and through the windpipe. | The ventilator tube does not go into the mouth and through the windpipe. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_3 | yes | Sometimes there are bacteria on the ventilator tube that infect the patient's lungs, leading to a disease called ventilator‐associated pneumonia. | Sometimes there are bacteria on the ventilator tube that do not infect the patient's lungs, leading to a disease called ventilator‐associated pneumonia. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_4 | no | Ventilator‐associated pneumonia can cause significant harmful effects, and can sometimes lead to death. | Ventilator‐associated pneumonia can prevent significant harmful effects, and can sometimes lead to death. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_5 | yes | When treating people with ventilator‐associated pneumonia, doctors must decide which antibiotic therapy to prescribe, usually without knowing the particular type of bacterial infection. | When treating people with ventilator‐associated pneumonia, doctors must decide which antiviral therapy to prescribe, usually without knowing the particular type of bacterial infection. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_6 | no | This decision is important because inappropriate initial treatment may increase risk of harmful effects and longer hospital stays. | This decision is important because inappropriate initial treatment may decrease risk of harmful effects and longer hospital stays. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_7 | no | We looked at studies involving adults aged over 18 years who were treated in intensive care units for ventilator‐associated pneumonia and needed antibiotic treatment. | We looked at studies involving adults aged over 25 years who were treated in intensive care units for ventilator‐associated pneumonia and needed antibiotic treatment. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_8 | no | We analysed 12 studies with 3571 participants. | We analysed 15 studies with 3571 participants. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_9 | no | All included studies looked at the use of one antibiotic treatment plan versus another, but these varied among studies. | All included studies looked at the use of one antiviral treatment plan versus another, but these varied among studies. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_10 | no | There was potential for bias because some studies did not report outcomes for all participants, and funding for many was provided by pharmaceutical companies and study authors were affiliated with these companies. | There was potential for bias because some studies did not report outcomes for all participants, and funding for many was provided by biotechnology companies and study authors were affiliated with these companies. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_11 | no | We used statistical techniques to evaluate our results. | We used statistical techniques to ignore our results. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_12 | no | For single versus multiple antibiotics, we found no difference in rates of death or cure, or adverse events. | For single versus multiple antibiotics, we found a difference in rates of death or cure, or adverse events. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_13 | yes | For our comparison of combination therapies with optional adjunctives we were only able to analyse clinical cure for one the antibiotics Tigecycline and imipenem‐cilastatin for which imipenem‐cilastatin was found to have higher clinica cure. | For our comparison of combination therapies with optional adjunctives we were only able to analyse clinical cure for one the antibiotics Tigecycline and amoxicillin for which imipenem‐cilastatin was found to have higher clinical cure. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_14 | yes | We also looked at carbapenem (antibiotics used to treat infections caused by multidrug‐resistant bacteria) versus non‐carbapenem treatment; we found no difference in death rate or adverse effects, but we found that carbapenems are associated with an increase in clinical cure. | We also looked at carbapenem (antibiotics used to treat infections caused by multidrug‐resistant bacteria) versus non‐carbapenem treatment; we found no difference in death rate or adverse effects, but we found that carbapenems are associated with a decrease in clinical cure. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_15 | no | We did not find differences between single and combination therapy, lending support to use of a single‐antibiotic treatment plan for people with ventilator‐associated pneumonia. | We did not find differences between single and combination therapy, lending support to use of a multi‐antibiotic treatment plan for people with ventilator‐associated pneumonia. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t198 | t198_16 | yes | This may not be applicable to all patients because studies did not identify patients who are at risk of exposure to harmful types of bacteria. | This may not be applicable to all patients because studies did not identify patients who are at risk of exposure to beneficial types of bacteria. | Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically‐ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic ther... |
t199 | t199_1 | no | Acute respiratory infection (including pneumonia) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. | Acute respiratory infection (including pneumonia) is one of the leading causes of morbidity and mortality in children under seven years of age in developing countries. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_2 | no | Antibiotics are needed when a bacterial infection is suspected. | Antibiotics are not needed when a bacterial infection is suspected. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_3 | no | When children are hospitalised they often receive injectable antibiotics. | When children are hospitalised they often do not receive injectable antibiotics. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_4 | no | This has disadvantages: pain, risk of other infections and cost. | This has disadvantages: pain, risk of other infections and benefit. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_5 | yes | There are studies that show that oral antibiotics are effective when children are treated as outpatients. | There are studies that show that oral antivirals are effective when children are treated as outpatients. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_6 | no | The objective of this review was to determine the effectiveness and safety of oral antibiotics compared to parenteral antibiotics in the treatment of pneumonia in children less than five years old. | The objective of this review was to determine the effectiveness and safety of oral antibiotics compared to parenteral antibiotics in the treatment of pneumonia in children less than seven years old. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_7 | no | Oral therapy appears to be an effective and safe alternative to parenteral antibiotics in hospitalised children with severe pneumonia who do not have any serious signs or symptoms. | Oral therapy appears to be an ineffective and unsafe alternative to parenteral antibiotics in hospitalised children with severe pneumonia who do not have any serious signs or symptoms. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
t199 | t199_8 | yes | There is currently insufficient evidence to determine the relative benefits and harms of oral antibiotics in children with severe pneumonia if serious signs and symptoms are present or in children with severe pneumonia associated with bacterial confirmation or lobar consolidation on chest X‐ray. | There is currently insufficient evidence to determine the relative benefits and harms of oral antivirals in children with severe pneumonia if serious signs and symptoms are present or in children with severe pneumonia associated with bacterial confirmation or lobar consolidation on chest X‐ray. | Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it ca... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.